Hanall Biopharma한올바이오파마
009420 · KOSPI · ₩009420 · 한올바이오파마
₩37,800▼ ₩700 (1.82%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩155B | ₩139B | ₩135B | ₩110B | ₩102B |
| Cost of sales | ₩74B | ₩66B | ₩60B | ₩48B | ₩41B |
| Gross profit | ₩81B | ₩73B | ₩75B | ₩62B | ₩60B |
| Operating income | −₩916M | ₩230M | ₩2.2B | ₩1.5B | ₩10B |
| Net income | −₩5.6B | −₩1.8B | ₩3.5B | ₩251M | ₩8.9B |
| Net income to shareholders | −₩5.6B | −₩1.8B | ₩3.5B | ₩251M | ₩8.9B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩225B | ₩213B | ₩240B | ₩213B | ₩198B |
| Current assets | ₩85B | ₩85B | ₩114B | ₩112B | ₩119B |
| Cash and equivalents | ₩25B | ₩16B | ₩34B | ₩17B | ₩13B |
| Total liabilities | ₩64B | ₩45B | ₩54B | ₩45B | ₩35B |
| Current liabilities | ₩44B | ₩35B | ₩38B | ₩29B | ₩22B |
| Borrowings | ₩31B | — | — | — | — |
| Total equity | ₩162B | ₩168B | ₩186B | ₩168B | ₩163B |
| Shareholders' equity | ₩162B | ₩168B | ₩186B | ₩168B | ₩163B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩2.3B | ₩9.4B | ₩30B | ₩25B | ₩840M |
| Capital spending | ₩948M | — | — | — | — |
| Free cash flow | −₩3.3B | ₩9.4B | ₩30B | ₩25B | ₩840M |
Consolidated where available. Amounts in won.
Also known as: Hanall Biopharma / 한올바이오파마 / 009420 / KRX:009420
Source: KRX statistical information